NCT04117321

Brief Summary

The human intestinal tract harbors a diverse and complex microbial community, known as gut microbiota, which is critical in sustaining physiology, metabolism, nutrition and immune function. Dysbiosis of gut microbiota has been linked with obesity, hyperglycemia, hyperlipidemia, inflammatory bowel disease and other chronic inflammatory diseases. Gut microbiota is affected by host genetic markup, diet and life style; and therefore varied by human races and geographical locations. The development of gut microbiota starts before birth. The infant's microbiome can impact on human health in later life. The microbiome of pregnant women are associated with early-life microbiota of their offspring as well as growth, neurodevelopment and the development of allergic and neurocognitive disorders. Early childhood, when the microbiota is less mature and more malleable, is a golden age for microbiota manipulation to prevent disease. Studying microbiota at this golden age also allow us to dissect the development of a faulty microbiota and identify therapeutic targets to reverse it and cure diseases that are already developed.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20,000

participants targeted

Target at P75+ for all trials

Timeline
17mo left

Started Sep 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress83%
Sep 2019Oct 2027

Study Start

First participant enrolled

September 23, 2019

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

October 3, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 7, 2019

Completed
7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 2, 2026

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

October 2, 2027

Last Updated

May 29, 2024

Status Verified

May 1, 2024

Enrollment Period

7 years

First QC Date

October 3, 2019

Last Update Submit

May 26, 2024

Conditions

Keywords

Mommy

Outcome Measures

Primary Outcomes (1)

  • Develop a 100,000 pair of mother-baby longitudinal cohort

    Set up a large scale database to collect data such as comprehensive clinical data, such as mother's and father's demographic and clinical information (e.g. age, weight, gender, family medical history, dietary, drug usage etc.)

    8 year

Secondary Outcomes (2)

  • Dissect the important microbiome that maintain health

    8 year

  • Seize the golden period of early life for prevention of human diseases

    8 year

Study Arms (3)

Pregnant women

Women who are being pregnant and plan to give birth in local hospital. Pregnant women who plan to stay in the same local area for at least 7 years post-delivery.

New Born Baby

new born baby of an enrolled pregnant woman.

Father of new born baby

Biological father of an enrolled new born baby.

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

This project will consist of a total 100,000 mother-baby pairs from all centers in 7 years. The study is exploratory in nature. In considering the number of events required for reliable quantification of different factors on a range of diseases, we decided to include 100,000 mother-baby pairs.

You may qualify if:

  • Being pregnant
  • Plan to give birth in local hospital
  • Competent to provide informed consent (no mental illness or dementia, etc. that will hinder their ability to undertake informed consent)

You may not qualify if:

  • Be a new born baby of an enrolled pregnant woman
  • Biological father of an enrolled new born baby

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Prince of Wales Hospital

Hong Kong, Hong Kong, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Blood, urine, stool, saliva, hair, nail, nasopharyngeal swab, skin swab, buccal swab, placenta, cord blood, low Vaginal swab and breast milk samples

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

October 3, 2019

First Posted

October 7, 2019

Study Start

September 23, 2019

Primary Completion (Estimated)

October 2, 2026

Study Completion (Estimated)

October 2, 2027

Last Updated

May 29, 2024

Record last verified: 2024-05

Locations